Latest Clinical Evidence Points to Paragonix SherpaPak as a Tool to Reduce Unpredictable, Severe Complications following Heart Transplantation

GUARDIAN Registry data presented at ACC 2023 has shown use of the Paragonix SherpaPak Cardiac Transport System was associated with improved outcomes as compared to the use of traditional cold storage in LVAD patients undergoing Heart Transplantation

Related Keywords

United States , American , Joseph Lerman , Paragonix Sherpapak , Lisa Anderson , American Association Of Cardiology Annual Meeting , Paragonix Technologies Inc , Center Early , Paragonix Technologies , Cardiac Transport System , Cardiology Annual Meeting , Heart Registry , Primary Graft Function , Clinical Research Fellow , Duke Clinical Research , Advanced Organ Preservation ,